Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotility

被引:29
作者
Dalziel, J. E. [1 ]
Young, W. [1 ]
Bercik, P. [2 ]
Spencer, N. J. [3 ]
Ryan, L. J. [1 ]
Dunstan, K. E. [1 ]
Lloyd-West, C. M. [4 ]
Gopal, P. K. [5 ,8 ]
Haggarty, N. W. [5 ]
Roy, N. C. [1 ,6 ,7 ]
机构
[1] AgResearch, Food & Biobased Prod Grp, Food Nutr & Hlth Team, Palmerston North, New Zealand
[2] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Dept Med, Hamilton, ON, Canada
[3] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia
[4] AgResearch, Bioinformat Math & Stat, Palmerston North, New Zealand
[5] Fonterra Cooperat Grp, Palmerston North, New Zealand
[6] Massey Univ, Riddet Inst, Palmerston North, New Zealand
[7] Univ Auckland, Gravida Natl Ctr Growth & Dev, Auckland, New Zealand
[8] Plant & Food Res, Palmerston North, New Zealand
关键词
colon transit; constipation; gastrointestinal transit; loperamide; prucalopride; LOPERAMIDE-INDUCED CONSTIPATION; IRRITABLE-BOWEL-SYNDROME; IN-VIVO; POSTOPERATIVE ILEUS; INTESTINAL MOTILITY; HUMAN COLON; PRUCALOPRIDE; MOTOR; TRACT; VITRO;
D O I
10.1111/nmo.12824
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Dysmotility in the gastrointestinal (GI) tract often leads to impaired transit of luminal contents leading to symptoms of diarrhea or constipation. The aim of this research was to develop a technique using high resolution X-ray imaging to study pharmacologically induced aged rat models of chronic GI dysmotility that mimic accelerated transit (diarrhea) or constipation. The 5-hydroxytryptamine type 4 (5-HT4) receptor agonist prucalopride was used to accelerate transit, and the opioid agonist loperamide was used to delay transit. Methods Male rats (18 months) were given 0, 1, 2, or 4 mg/kg/day prucalopride or loperamide (in dimethyl sulfoxide, DMSO) for 7 days by continuous 7-day dosing. To determine the GI region-specific effect, transit of six metallic beads was tracked over 12 h using high resolution X-ray imaging. An established rating scale was used to classify GI bead location in vivo and the distance beads had propagated from the caecum was confirmed postmortem. Key Results Loperamide (1 mg/kg) slowed stomach emptying and GI transit at 9 and 12 h. Prucalopride (4 mg/kg) did not significantly alter GI transit scores, but at a dose of 4 mg/kg beads had moved significantly more distal than the caecum in 12 h compared to controls. Conclusions & Inferences We report a novel high-resolution, non-invasive, X-ray imaging technique that provides new insights into GI transit rates in live rats. The results demonstrate that loperamide slowed overall transit in aged rats, while prucalopride increased stomach emptying and accelerates colonic transit.
引用
收藏
页码:1241 / 1251
页数:11
相关论文
共 51 条
[1]   In vitro and non-invasive invivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat [J].
Abalo, R. ;
Chen, C. ;
Vera, G. ;
Fichna, J. ;
Thakur, G. A. ;
Lopez-Perez, A. E. ;
Makriyannis, A. ;
Martin-Fontelles, M. I. ;
Storr, M. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2015, 27 (12) :1721-1735
[2]   The pharmacology of TD-8954, a potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties [J].
Beattie, David T. ;
Armstrong, Scott R. ;
Vickery, Ross G. ;
Tsuruda, Pamela R. ;
Campbell, Christina B. ;
Richardson, Carrie ;
McCullough, Julia L. ;
Daniels, Oranee ;
Kersey, Kathryn ;
Li, Yu-Ping ;
Kim, Karl H. S. .
FRONTIERS IN PHARMACOLOGY, 2011, 2
[3]   Effect of age on the enteric nervous system of the human colon [J].
Bernard, C. E. ;
Gibbons, S. J. ;
Gomez-Pinilla, P. J. ;
Lurken, M. S. ;
Schmalz, P. F. ;
Roeder, J. L. ;
Linden, D. ;
Cima, R. R. ;
Dozois, E. J. ;
Larson, D. W. ;
Camilleri, M. ;
Zinsmeister, A. R. ;
Pozo, M. J. ;
Hicks, G. A. ;
Farrugia, G. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (07) :746-E46
[4]   Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans [J].
Bouras, EP ;
Camilleri, M ;
Burton, DD ;
McKinzie, S .
GUT, 1999, 44 (05) :682-686
[5]   The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound [J].
Briejer, MR ;
Bosmans, JP ;
Van Daele, P ;
Jurzak, M ;
Heylen, L ;
Leysen, JE ;
Prins, NH ;
Schuurkes, JAJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 423 (01) :71-83
[6]   ACTION OF OPIATES ON GASTROINTESTINAL FUNCTION [J].
BUENO, L ;
FIORAMONTI, J .
BAILLIERES CLINICAL GASTROENTEROLOGY, 1988, 2 (01) :123-139
[7]  
Buiter H. J., 2013, EUR J NUCL MED MOL I, V3, P3
[8]   Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome [J].
Camilleri, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (01) :44-59
[9]   Opiate-induced constipation related to activation of small intestine opioid μ2-receptors [J].
Chen, Wency ;
Chung, Hsien-Hui ;
Cheng, Juei-Tang .
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (12) :1391-1396
[10]   Neurogenic and myogenic motor activity in the colon of the guinea pig, mouse, rabbit, and rat [J].
Costa, M. ;
Dodds, K. N. ;
Wiklendt, L. ;
Spencer, N. J. ;
Brookes, S. J. H. ;
Dinning, P. G. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2013, 305 (10) :G749-G759